Lmcg Investments LLC Has $31.85 Million Stock Holdings in AbbVie Inc. $ABBV

Lmcg Investments LLC lowered its position in AbbVie Inc. (NYSE:ABBV) by 2.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 139,376 shares of the company’s stock after selling 3,864 shares during the period. AbbVie accounts for 1.8% of Lmcg Investments LLC’s portfolio, making the stock its 9th largest holding. Lmcg Investments LLC’s holdings in AbbVie were worth $31,846,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie in the third quarter valued at approximately $31,000. WestEnd Advisors LLC raised its stake in shares of AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Finally, Caitlin John LLC bought a new position in AbbVie in the 3rd quarter worth approximately $33,000. Institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New long‑term gastroenterology data — AbbVie presented 18 abstracts at Digestive Disease Week showing supportive long‑term and real‑world data for SKYRIZI (risankizumab) and RINVOQ (upadacitinib), which can bolster label positioning and commercial durability in IBD. AbbVie Highlights New Long-Term Data at DDW (PR Newswire)
• Positive Sentiment: Dividend appeal — several income-oriented outlets featured AbbVie as a high‑yield, reliable dividend stock (Dividend King), which supports steady investor demand from income-focused funds. 6 Pharma Dividend Stocks Yielding Up to 6.44% (247WallSt)
• Positive Sentiment: Investor visibility — management will appear at the Bank of America Securities Healthcare Conference on May 13 (fireside chat), offering a chance for updated commercial color or guidance that could move the stock. AbbVie to Present at the Bank of America Securities Healthcare Conference (PR Newswire)
• Neutral Sentiment: Analyst/retail interest — multiple trending and “is it a buy?” pieces are driving attention but offer mixed views; useful for gauging retail flow rather than immediate fundamental change. Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
• Neutral Sentiment: Strategic/tech engagement — AbbVie appeared among industry leaders at Zifo’s SiEE summit on practical AI in life sciences; longer‑term operational upside but unclear near‑term impact. Zifo’s SiEE Boston Summit Charts New Roadmap (Yahoo)
• Neutral Sentiment: Peripheral industry moves — news such as Timothy P. Walbert joining Patient Square is industry‑level and not directly tied to AbbVie fundamentals. Timothy P. Walbert Joins Patient Square Capital (Yahoo)
• Negative Sentiment: Regulatory/manufacturing setback — the U.S. FDA declined to approve AbbVie’s wrinkle treatment over manufacturing concerns (reported April 23), highlighting execution and regulatory risk that can weigh on aesthetics revenue and investor confidence. FDA Declines Approval of AbbVie Wrinkle Treatment (MSN)

Analyst Upgrades and Downgrades

ABBV has been the subject of several research analyst reports. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Citigroup dropped their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $252.90.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

Shares of AbbVie stock opened at $205.14 on Thursday. The firm has a fifty day moving average of $213.69 and a two-hundred day moving average of $221.19. The stock has a market capitalization of $362.72 billion, a price-to-earnings ratio of 101.05, a PEG ratio of 0.71 and a beta of 0.32. AbbVie Inc. has a 52 week low of $176.57 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 EPS. As a group, research analysts forecast that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie’s payout ratio is presently 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.